MEDPOLICYGPWCKZNECLPMPNWFSNC SAnews.gov.za
The ARC's decision to license its FMD vaccine IP to private companies is a strategic move to overcome manufacturing bottlenecks. This opens the door for private firms to bid for licensing agreements and related supply contracts, potentially transforming the vaccine procurement landscape in South Africa. While it addresses immediate outbreak response needs, it also signals a broader trend of public-private collaboration in critical sectors.
This increases vaccine supply capacity, which is critical for controlling FMD outbreaks, and creates new business opportunities for manufacturers and suppliers in the agricultural and pharmaceutical sectors.
ARC will now allow private companies to manufacture its FMD vaccine under conditional IP licensing agreements.
This move could set a precedent for other state-owned entities to leverage private sector capabilities, potentially increasing competition and innovation in public procurement. It may also lead to more resilient supply chains for critical vaccines, reducing reliance on single producers.
Suppliers of vaccine production equipment, raw materials, and logistics services should monitor ARC and Department of Agriculture tenders. Companies with GMP certification and experience in vaccine manufacturing are well-positioned to bid for licensing agreements.
Bidders must ensure compliance with IP licensing terms, quality standards (e.g., GMP), and biosecurity regulations. Failure to meet these could lead to contract termination or legal action.
Excerpt reproduced for context. Tenders SA analysis is based on this public source. Read the full article at SAnews.gov.za.
Stay ahead of procurement changes